Rein Therapeutics, Inc.
Rein Therapeutics, Inc. is a U.S.-based clinical-stage biopharmaceutical company focused on developing inhaled therapies for fibrotic and other serious lung diseases. Its pipeline includes LTI-03 for idiopathic pulmonary fibrosis and LTI-01 for lung-related indications, with development activities conducted through clinical research partners and external manufacturing and regulatory support.
Fiscal year 2025 · change from previous year
Development 2020–2025
Business
Share of revenueInhaled peptide candidate being developed for idiopathic pulmonary fibrosis.
Earlier-stage lung disease product candidate in the company pipeline.
Outsourced clinical trial execution, monitoring, and study operations for pipeline programs.
Animal studies, toxicology work, and supporting research required before and during trials.
Regulatory consulting, manufacturing, and clinical supply activities tied to development.
Customers
Rein Therapeutics does not sell commercial products; its primary counterparties are clinical research organizations, manufacturers, regulators, and development partners that support its drug pipeline. The eventual end customers for approved therapies would be physicians, hospitals, and patients in pulmonary and fibrotic lung disease markets. The company also engages potential licensing or asset-sale counterparties for non-core programs such as ALRN-6924.
They perform trial management and study execution for LTI-03 and other programs.
They supply clinical materials, testing, and development support needed for trials.
They review safety, toxicology, and clinical data needed to advance candidates.
They may acquire or license non-core assets such as oncology programs.
They would use approved therapies for fibrotic lung disease and related indications.
Strategy
The company’s strategy is to advance LTI-03 and LTI-01 through preclinical and clinical development while expanding its pipeline through acquisition or in-licensing. It relies on outsourced research, manufacturing, and regulatory capabilities to progress programs efficiently and to preserve flexibility around future partnering or commercialization options. International trial expansion is part of the development plan to maintain momentum while U.S. regulatory issues are addressed.
LTI-03 is the lead asset and the main driver of future value creation.
Additional candidates reduce dependence on a single program and broaden optionality.
Outsourced CRO, manufacturing, and regulatory support are essential to move programs forward.
Geography
Rein Therapeutics is headquartered in the United States and conducts most of its development and corporate activities from there. Its clinical footprint is broader, with trial activity and site activation planned across the United States, Australia, the United Kingdom, and Europe for LTI-03. Geography matters because regulatory requirements, trial access, and site availability can differ materially by country.
Risks
The company faces high clinical and regulatory risk because its value depends on successful trial execution, nonclinical support, and eventual FDA approval. It also depends on external financing and third-party vendors, so delays, clinical holds, or funding shortfalls can materially slow or stop development programs. As a single-asset-leaning biotech, it is also exposed to pipeline concentration and intellectual property risk.
The lead Phase 2 trial was placed on hold pending additional nonclinical work.
Exposure: LTI-03 RENEW Phase 2 trial
The company needs external capital to fund trials, manufacturing, and operations.
Exposure: Corporate liquidity and development programs
Drug candidates may not demonstrate safety, tolerability, or efficacy in humans.
Exposure: LTI-03 and LTI-01
Clinical and manufacturing work is outsourced and depends on vendor performance.
Value depends on protecting assets and maintaining collaboration or licensing options.
Exposure: Pipeline assets and future commercialization
Accounting
Judgemental itemsTrial and CRO costs are recognized as services are received and estimated when invoices lag.
Impact: Can shift quarterly R&D expense materially
Expired or unusable materials may need to be written off when programs change or pause.
Impact: Can create one-time expense spikes
Offering warrants and other equity instruments require valuation and dilution tracking.
Impact: Affects equity, earnings per share, and capital structure
Option fees, milestones, and royalties depend on future events and contract terms.
Impact: Can affect other income, liabilities, or future cash flows
Similar listed companies
Publicly listed companies with a comparable business focus.
Inhibikase Therapeutics, Inc.
IKT · Biological Products, (No Diagnostic Substances)
BriaCell Therapeutics Corp.
BCTX · Pharmaceutical Preparations
Relay Therapeutics, Inc.
RLAY · Biological Products, (No Diagnostic Substances)
Intensity Therapeutics, Inc
INTS · Biological Products, (No Diagnostic Substances)
Context Therapeutics Inc.
CNTX · Pharmaceutical Preparations
United Therapeutics Corporation
UTHR · Pharmaceutical Preparations
United Therapeutics is a U.S.-based biopharmaceutical company focused on therapies for pulmonary arterial hypertension and other serious rare diseases, along with organ manufacturing technologies.
Last updated: 24/09/2026